Ozempic will disrupt big tobacco, candy companies, and alcohol brands

Scope of Ozempic/GLP‑1 Effects

• Many see GLP‑1 agonists (Ozempic, Wegovy, Mounjaro, etc.) as the most effective and safest weight‑loss drugs yet, with strong appetite/craving reduction and possible addiction benefits.
• Some anecdotal reports: food becomes less salient (“food noise” down), smaller portions, less interest in high‑reward foods; others still want treats but in reduced amounts.
• There is speculation they could reduce consumption of junk food, alcohol, tobacco, and even gambling, with big implications for those industries.

Long‑Term Use, “Lifestyle” vs. Medication

• One camp: obesity is largely behavioral/environmental; drugs should be a temporary “reset” while people fix diet and exercise.
• Another camp: for most obese people, behavior programs fail at scale; GLP‑1s will function like statins or insulin—lifelong treatments that are still “miles better than the alternative.”
• Some worry about a dystopian reliance on drugs to compensate for unhealthy environments; others frame that as rational “body‑hacking” for a modern world our biology isn’t adapted to.

Efficacy, Relapse, and Alternatives

• Claims that most people regain much of the weight after stopping; others counter that rebound is partial (e.g., ~5% net loss) and still worthwhile.
• Strong disagreement about how often obesity or type 2 diabetes can be reversed “naturally” via low‑carb, fasting, or ketogenic diets; thread cites papers both for and against broad generalization.
• GLP‑1s are contrasted with surgery, stimulants (Adderall/meth), and behavioral programs.

Safety and Side Effects

• GLP‑1 agonists have been in use since mid‑2000s, but very long‑term effects (multi‑decade, brain/reward‑system impacts, cancer risk) are seen as uncertain.
• Known or reported side effects: GI issues (constipation/diarrhea/bloating), occasional acid reflux, possible sleep issues, and one report of low libido/ED.
• Several argue that, given the high health risk of obesity/addiction, GLP‑1 risks are likely the lesser evil, but this is not definitively settled.

Price, Access, and Pharma Incentives

• US price ($1,000/month) vs. very low estimated manufacturing cost ($5/month) is heavily criticized.
• Discussion of patents, “evergreening,” dosage/formulation strategies, and compounding pharmacies; some see emerging competition (other GLP‑1s, oral forms, India/China generics) as eventual price relief.
• Debate over price controls vs. market incentives, and whether current systems push pharma toward chronic treatments over one‑shot cures.